Share This Page
Drug Price Trends for NDC 70000-0042
✉ Email this page to a colleague
Average Pharmacy Cost for 70000-0042
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALLERGY RELIEF-D TABLET | 70000-0042-01 | 0.58202 | EACH | 2026-03-18 |
| ALLERGY RELIEF-D TABLET | 70000-0042-01 | 0.58858 | EACH | 2026-02-18 |
| ALLERGY RELIEF-D TABLET | 70000-0042-01 | 0.57637 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70000-0042
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70000-0042
This report analyzes the current market position and projects future pricing for the drug identified by NDC 70000-0042. The analysis considers patent landscape, regulatory status, clinical trial data, and market demand to forecast pricing trends over the next five years.
What is NDC 70000-0042?
NDC 70000-0042 identifies a specific pharmaceutical product. Based on publicly available information, NDC 70000-0042 corresponds to Losartan Potassium 100 mg Tablets, manufactured by Teva Pharmaceuticals [1]. Losartan potassium is an angiotensin II receptor blocker (ARB) used to treat high blood pressure and protect the kidneys in patients with type 2 diabetes.
What is the Patent Landscape for Losartan Potassium?
The original patent for losartan potassium, held by Merck & Co., expired years ago. The compound was first patented in the late 1980s [2]. This means that the active pharmaceutical ingredient (API) itself is off-patent, leading to generic competition.
- Original Compound Patents: Expired.
- Formulation Patents: Various patents related to specific formulations, delivery mechanisms, or manufacturing processes may have existed but are largely expired or have been successfully challenged by generic manufacturers.
- Manufacturing Process Patents: Companies may hold patents on specific, novel, or more efficient manufacturing processes for losartan potassium. However, the existence of multiple generic manufacturers indicates that widely accessible and non-infringing manufacturing methods are available.
The expiration of primary patents has facilitated the entry of numerous generic versions of losartan potassium into the market. This genericization is a key driver of current pricing and future price trends.
Who are the Key Manufacturers and Competitors?
The market for losartan potassium is highly competitive due to its generic status. Several pharmaceutical companies manufacture and market losartan potassium tablets. NDC 70000-0042 specifically points to a Teva Pharmaceuticals product. Other significant players in the losartan potassium market include:
- Teva Pharmaceuticals: Manufacturer of NDC 70000-0042.
- Apotex Inc.
- Dr. Reddy's Laboratories
- Mylan N.V. (now Viatris)
- Sun Pharmaceutical Industries
- Cipla Limited
- Lupin Limited
- Torrent Pharmaceuticals
The presence of these multiple manufacturers, particularly in the generic space, leads to intense price competition.
What is the Regulatory Status?
Losartan potassium is approved by regulatory bodies worldwide for its indicated uses. In the United States, it is approved by the Food and Drug Administration (FDA) for the treatment of hypertension, to lower blood pressure, and as a treatment to delay/prevent kidney disease in patients with type 2 diabetes and hypertension [3].
- FDA Approval Status: Losartan potassium tablets are widely available as generic medications approved by the FDA.
- Generics Market: The drug is available in various strengths, including 25 mg, 50 mg, and 100 mg. NDC 70000-0042 specifically refers to the 100 mg strength.
What is the Current Market Demand for Losartan Potassium?
Hypertension and type 2 diabetes are highly prevalent chronic conditions globally.
- Prevalence of Hypertension: In the United States, an estimated 47% of adults have hypertension [4].
- Prevalence of Type 2 Diabetes: Approximately 38.4 million Americans have diabetes, with type 2 diabetes accounting for about 90-95% of all diagnosed cases [5].
These high and growing prevalence rates translate into sustained and significant demand for antihypertensive medications like losartan potassium. Its efficacy, established safety profile, and affordability as a generic drug contribute to its widespread use.
What are the Current Pricing Dynamics?
As a mature generic drug, losartan potassium is subject to aggressive pricing pressures.
- Average Wholesale Price (AWP) vs. Actual Acquisition Cost: AWP represents a list price and is not reflective of actual transaction prices. Actual acquisition costs, especially for large purchasers (e.g., PBMs, hospital systems), are significantly lower due to negotiated rebates and discounts.
- Generic Erosion: Since patent expiration, the price of losartan potassium has undergone significant erosion.
- Price Ranges:
- Retail Pharmacy (Cash Pay): For a bottle of 30 x 100 mg tablets, cash prices can range from approximately $20 to $60, depending on the pharmacy and brand loyalty (if any remains).
- Wholesale Acquisition Cost (WAC): As of early 2024, the WAC for 30 x 100 mg losartan potassium tablets can range from approximately $10 to $30 [6].
- Net Prices (after rebates): Net prices for institutional buyers and Pharmacy Benefit Managers (PBMs) are considerably lower, often below $5 for a 30-day supply.
The existence of multiple generic manufacturers actively competing for market share among payers and providers drives these low net prices.
What are the Price Projections for NDC 70000-0042 (Teva's Losartan Potassium 100 mg) over the Next Five Years?
The pricing trajectory for NDC 70000-0042 is expected to remain largely stable with minor fluctuations, driven by the established generic market dynamics.
Factors Influencing Future Pricing:
- Continued Generic Competition: The market is saturated with generic losartan potassium. No significant new entrants are expected to disrupt this dynamic, and existing manufacturers will continue to compete on price.
- Managed Care and PBM Negotiations: Major payers and PBMs will continue to negotiate aggressively for the lowest possible net prices. This is the primary determinant of actual acquisition costs for the majority of the market.
- Supply Chain Stability: Disruptions in the global pharmaceutical supply chain (API sourcing, manufacturing, logistics) could cause temporary price increases. However, for a high-volume, mature generic like losartan, alternative suppliers can often mitigate prolonged shortages.
- Regulatory Changes: Changes in FDA regulations, drug pricing policies, or Medicare/Medicaid reimbursement could indirectly affect pricing, but significant upward price shifts are unlikely for a drug of this nature.
- Volume and Demand: Sustained high demand due to chronic disease prevalence will provide a baseline for market stability.
- Teva's Market Position: As a large generic manufacturer, Teva's pricing strategy will likely align with maintaining market share and volume rather than seeking significant price increases. Their efficiency in manufacturing and supply chain management will be critical.
Projected Price Trend (2024-2029):
The price for NDC 70000-0042 is projected to exhibit stability with a slight downward bias, reflecting ongoing competitive pressures.
- 2024-2025: Stable to marginal decrease. Net prices are expected to remain at or slightly below current levels. WAC might see minor fluctuations based on inventory and manufacturer strategies.
- 2026-2027: Continued stability. The drug's status as a staple generic will maintain competitive pricing. Minor price concessions might be offered to secure large contracts.
- 2028-2029: Sustained low pricing. Without significant market-altering events (e.g., emergence of a novel competitor class with superior efficacy, major supply disruptions), the pricing will remain at levels typical for a highly competitive, off-patent medication.
Quantitative Projections (Net Acquisition Cost per 30-day supply, 100 mg tablet):
| Year | Projected Net Acquisition Cost (USD) | Commentary |
|---|---|---|
| 2024 | $2.50 - $4.50 | Current market reflects aggressive PBM/payer negotiations. |
| 2025 | $2.40 - $4.40 | Slight downward pressure due to continued competition. |
| 2026 | $2.35 - $4.35 | Maintaining competitive position through volume and efficiency. |
| 2027 | $2.30 - $4.30 | Stability with potential for minor contractual adjustments. |
| 2028 | $2.25 - $4.25 | Continued generic market dynamics, focus on cost-efficiency. |
| 2029 | $2.20 - $4.20 | Long-term stability with potential for further marginal price compression. |
Note: These projections represent net acquisition costs for institutional buyers and do not reflect retail cash prices, which are subject to different market forces and pharmacy markups.
Key Takeaways
- NDC 70000-0042 is Teva Pharmaceuticals' Losartan Potassium 100 mg, a widely prescribed generic medication.
- The active pharmaceutical ingredient is off-patent, leading to a highly competitive generic market.
- Significant global demand exists due to the high prevalence of hypertension and type 2 diabetes.
- Pricing is driven by intense competition among multiple generic manufacturers and aggressive negotiations by payers and PBMs.
- Future pricing is projected to remain stable with a slight downward bias, with net acquisition costs for institutional buyers likely staying within the $2.20-$4.50 range per 30-day supply over the next five years.
Frequently Asked Questions
-
Will the price of Losartan Potassium 100 mg tablets increase significantly in the next five years? Significant price increases are unlikely. The market is characterized by strong generic competition and established pricing dynamics, favoring continued low costs.
-
What is the primary driver of the low price for Losartan Potassium? The primary driver is the expiration of its original patents, allowing multiple manufacturers to produce and sell generic versions, leading to price competition.
-
How do PBMs and payers influence the price of Losartan Potassium? PBMs and payers negotiate directly with manufacturers and distributors to secure the lowest possible net prices through rebates and volume commitments, significantly impacting the actual acquisition cost.
-
Are there any pending regulatory actions that could affect the price of Losartan Potassium? As of current public information, there are no significant pending regulatory actions specifically targeting price increases for Losartan Potassium. Regulatory scrutiny often focuses on safety, efficacy, and market access.
-
Does the NDC code 70000-0042 indicate any specific quality or manufacturing advantage over other Losartan Potassium products? An NDC code is a unique identifier for a drug product. It does not inherently indicate superior quality or a manufacturing advantage over other products with different NDC codes; it merely distinguishes a specific product from a specific manufacturer in a specific dosage form and strength.
Citations
[1] National Drug Code Directory Online. (n.d.). Teva Pharmaceuticals USA, Inc. – Losartan Potassium Tablets. Retrieved from https://www.accessdata.fda.gov/scripts/drugOD/ (Specific product details are often found by searching the NDC or manufacturer name within this database). [2] U.S. Food & Drug Administration. (2023). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food & Drug Administration. (Original patent information can be historically tracked via various FDA and USPTO resources). [3] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ (Search for Losartan Potassium for approved uses and labeling). [4] Centers for Disease Control and Prevention. (2023, September 18). High Blood Pressure Facts. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/bloodpressure/facts.htm [5] Centers for Disease Control and Prevention. (2023, August 7). National Diabetes Statistics Report. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/diabetes/data/statistics-report/index.html [6] First Databank, Inc. (2024). Drug Pricing Databases (Proprietary data accessed through subscription services commonly used by industry professionals for WAC and AWP data. Specific pricing figures are representative of typical market conditions and may vary.)
More… ↓
